Drug Company Reverses Course on Controversial Price Hike
A pharmaceuticals company that raised the price of a drug 5,500 practically overnight says it will now lower its price following intense backlash. Turing Pharmaceuticals founder Martin Shkreli confirmed the price cut to NBC News on Tuesday but did not say how much the company would reduce the cost of Daraprim. Early this week, Turing's decision to raise the price of Daraprim from 13.50 a tablet to 750 was the subject of a New York Times story. The drug, which is generically known as pyrimethamine and was acquired by the company acquired in August, is used to treat a serious parasitic infection called toxoplasmosis, which can be life-threatening for those with compromised immune systems. It's also been used to treat malaria. Shkreli said the new price will allow the company to break even or make a "small profit" on the drug. NBC News